Compare EBAY & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EBAY | ONC |
|---|---|---|
| Founded | 1995 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | 12000 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.4B | 31.4B |
| IPO Year | 1998 | N/A |
| Metric | EBAY | ONC |
|---|---|---|
| Price | $95.92 | $303.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 28 | 12 |
| Target Price | $97.23 | ★ $374.75 |
| AVG Volume (30 Days) | ★ 4.2M | 182.1K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.27% | N/A |
| EPS Growth | ★ 10.15 | N/A |
| EPS | ★ 4.34 | N/A |
| Revenue | ★ $17,902,000,000.00 | N/A |
| Revenue This Year | $10.44 | $747.23 |
| Revenue Next Year | $5.06 | $15.78 |
| P/E Ratio | ★ $22.50 | $614.06 |
| Revenue Growth | ★ 11.56 | N/A |
| 52 Week Low | $58.97 | $196.53 |
| 52 Week High | $101.15 | $385.22 |
| Indicator | EBAY | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 63.28 | 52.14 |
| Support Level | $87.29 | $295.97 |
| Resistance Level | $97.97 | $311.10 |
| Average True Range (ATR) | 2.72 | 7.59 |
| MACD | 0.69 | 4.85 |
| Stochastic Oscillator | 81.63 | 71.79 |
EBay operates one of the largest e-commerce marketplaces in the world, with $75 billion in 2024 gross merchandise volume, rendering the firm a top 10 global e-commerce company. It generates sales from listing fees, advertising, revenue-sharing arrangements with service providers, and managed payments, with its platform connecting more than 130 million buyers and roughly 20 million sellers across almost 190 global markets at the end of 2024. EBay generates just north of 50% of its GMV in international markets, with a large presence in the UK, Germany, and Australia.
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.